{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T20:00:04Z","timestamp":1722888004410},"reference-count":71,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Cl\u00ednica Espa\u00f1ola"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.rce.2018.09.021","type":"journal-article","created":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T05:42:14Z","timestamp":1544679734000},"page":"208-217","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tratamiento diur\u00e9tico del paciente con diabetes e insuficiencia cardiaca. El papel de los inhibidores de la SGLT2 y semejanzas con los inhibidores de la anhidrasa carb\u00f3nica"],"prefix":"10.1016","volume":"219","author":[{"given":"D.","family":"Le\u00f3n Jim\u00e9nez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"G\u00f3mez Huelgas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.J.","family":"Fern\u00e1ndez Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"L\u00f3pez Chozas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"P\u00e9rez de Isla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.P.","family":"Miramontes Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rce.2018.09.021_bib0360","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation."},{"key":"10.1016\/j.rce.2018.09.021_bib0365","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1253\/circj.CJ-16-0780","article-title":"Diuretic action of sodium-glucose cotransporter 2 inhibitors and its importance in the management of heart failure","volume":"80","author":"Kimura","year":"2016","journal-title":"Circ J."},{"key":"10.1016\/j.rce.2018.09.021_bib0370","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.2337\/diacare.21.9.1414","article-title":"Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections","volume":"21","author":"King","year":"1998","journal-title":"Diabetes Care."},{"key":"10.1016\/j.rce.2018.09.021_bib0375","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.rce.2018.09.021_bib0380","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1007\/s00125-012-2579-0","article-title":"High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes","volume":"55","author":"Boonman-de Winter","year":"2012","journal-title":"Diabetologia."},{"key":"10.1016\/j.rce.2018.09.021_bib0385","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1136\/hrt.2009.183624","article-title":"Diabetes: A driver for heart failure","volume":"97","author":"Voors","year":"2011","journal-title":"Heart."},{"key":"10.1016\/j.rce.2018.09.021_bib0390","doi-asserted-by":"crossref","first-page":"1167.e1","DOI":"10.1016\/j.recesp.2016.10.014","article-title":"Gu\u00eda ESC 2016 sobre el diagn\u00f3stico y tratamiento de la insuficiencia cardiaca aguda y cr\u00f3nica","volume":"69","author":"Ponikowski","year":"2016","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.rce.2018.09.021_bib0395","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/ejhf.137","article-title":"Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction","volume":"16","author":"Lund","year":"2014","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.rce.2018.09.021_bib0400","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2337\/diacare.13.11.1169","article-title":"Diabetic cardiomyopathy","volume":"13","author":"Fein","year":"1990","journal-title":"Diabetes Care."},{"key":"10.1016\/j.rce.2018.09.021_bib0405","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0002-9149(91)90716-X","article-title":"Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study)","volume":"68","author":"Galderisi","year":"1991","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.rce.2018.09.021_bib0410","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ejhf.1170","article-title":"Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Seferovi\u0107","year":"2018","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.rce.2018.09.021_bib0415","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","article-title":"Intensive glucose control and macrovascular outcomes in type 2 diabetes","volume":"52","author":"Turnbull","year":"2009","journal-title":"Diabetologia."},{"key":"10.1016\/j.rce.2018.09.021_bib0420","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.2337\/diacare.28.10.2345","article-title":"Improved clinical outcomes associated with metformin in patients with diabetes and heart failure","volume":"28","author":"Eurich","year":"2005","journal-title":"Diabetes Care."},{"key":"10.1016\/j.rce.2018.09.021_bib0425","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1161\/CIRCHEARTFAILURE.112.000162","article-title":"Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure systematic review of observational studies involving 34 000 patients","volume":"6","author":"Eurich","year":"2013","journal-title":"Circ Hear Fail."},{"key":"10.1016\/j.rce.2018.09.021_bib0430","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/ejhf.633","article-title":"Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes","volume":"19","author":"Fitchett","year":"2017","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.rce.2018.09.021_bib0435","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rce.2018.09.021_bib0440","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rce.2018.09.021_bib0445","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rce.2018.09.021_bib0450","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2337\/dc13-2116","article-title":"Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial\/epidemiology of diabetes interventions and complications study","volume":"37","author":"Lachin","year":"2014","journal-title":"Diabetes Care."},{"key":"10.1016\/j.rce.2018.09.021_bib0455","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rce.2018.09.021_bib0460","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rce.2018.09.021_bib0465","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rce.2018.09.021_bib0470","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rce.2018.09.021_bib0475","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation."},{"key":"10.1016\/j.rce.2018.09.021_bib0480","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/ejhf.933","article-title":"The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors","volume":"19","author":"Butler","year":"2017","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.rce.2018.09.021_bib0485","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: A \u201cthrifty substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.rce.2018.09.021_bib0490","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rce.2018.09.021_bib0495","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00125-016-3956-x","article-title":"SGLT2 inhibition and cardiovascular events: Why did EMPA-REG outcomes surprise and what were the likely mechanisms?","volume":"59","author":"Sattar","year":"2016","journal-title":"Diabetologia."},{"key":"10.1016\/j.rce.2018.09.021_bib0500","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.2337\/dc17-0061","article-title":"Dipeptidyl peptidase 4 inhibition stimulates distal tubular natriuresis and increases in circulating SDF-1\u03b11-67 in patients with type 2 diabetes","volume":"40","author":"Lovshin","year":"2017","journal-title":"Diabetes Care."},{"key":"10.1016\/j.rce.2018.09.021_bib0505","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.2337\/dc16-1371","article-title":"Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes: A 12-week, randomized, double-blind placebo-controlled trial","volume":"39","author":"Tonneijck","year":"2016","journal-title":"Diabetes Care."},{"key":"10.1016\/j.rce.2018.09.021_bib0510","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/jamacardio.2017.1891","article-title":"The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: The search for the sweet spot in heart failure","volume":"2","author":"Verma","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.rce.2018.09.021_bib0515","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.diabet.2016.05.006","article-title":"Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics","volume":"42","author":"Scheen","year":"2016","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.rce.2018.09.021_bib0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2015.07.072","article-title":"Diuretic effects of sodium-glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure","volume":"201","author":"Takeuchi","year":"2015","journal-title":"Int J Cardiol."},{"key":"10.1016\/j.rce.2018.09.021_bib0525","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jjcc.2011.12.007","article-title":"Comparative study of therapeutic effects of short- and long-acting loop diuretics in outpatients with chronic heart failure (COLD-CHF)","volume":"59","author":"Miyata","year":"2012","journal-title":"J Cardiol."},{"key":"10.1016\/j.rce.2018.09.021_bib0530","first-page":"229","article-title":"Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus","volume":"339","author":"Marx","year":"2016","journal-title":"Eur Heart J."},{"key":"10.1016\/j.rce.2018.09.021_bib0535","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.2008.250","article-title":"Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.rce.2018.09.021_bib0540","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation."},{"key":"10.1016\/j.rce.2018.09.021_bib0545","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12933-017-0654-z","article-title":"SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: A randomised controlled trial","volume":"17","author":"Karg","year":"2018","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.rce.2018.09.021_bib0550","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.rce.2018.09.021_bib0555","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/dom.12322","article-title":"Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus","volume":"16","author":"Sha","year":"2014","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.rce.2018.09.021_bib0560","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care."},{"key":"10.1016\/j.rce.2018.09.021_bib0565","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12933-018-0695-y","article-title":"Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy","volume":"17","author":"Irace","year":"2018","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.rce.2018.09.021_bib0570","article-title":"Acute pharmacodynamic effects of empagliflozin with and without diuretic agents in patients with type 2 diabetes mellitus","volume":"38","author":"Heise","year":"2016","journal-title":"Clin Ther."},{"key":"10.1016\/j.rce.2018.09.021_bib0575","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.clinthera.2014.02.022","article-title":"Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants","volume":"36","author":"Devineni","year":"2014","journal-title":"Clin Ther."},{"key":"10.1016\/j.rce.2018.09.021_bib0580","doi-asserted-by":"crossref","first-page":"e018097","DOI":"10.1136\/bmjopen-2017-018097","article-title":"Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): Protocol for a randomised controlled double-blind cross-over trial","volume":"7","author":"Mordi","year":"2017","journal-title":"BMJ Open."},{"key":"10.1016\/j.rce.2018.09.021_bib0585","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1161\/CIRCULATIONAHA.116.024764","article-title":"Use of sodium glucose cotransporter 2 inhibitors in the hands of cardiologists: With great power comes great responsibility","volume":"134","author":"Cherney","year":"2016","journal-title":"Circulation."},{"key":"10.1016\/j.rce.2018.09.021_bib0590","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdiacomp.2015.10.012","article-title":"EMPA-REG - The \u201cdiuretic hypothesis\u201d","volume":"30","author":"McMurray","year":"2016","journal-title":"J Diabetes Complications."},{"key":"10.1016\/j.rce.2018.09.021_bib0595","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2337\/dc16-0041","article-title":"SGLT2 inhibitors and cardiovascular risk: Lessons learned from the EMPA-REG OUTCOME study","volume":"39","author":"Abdul-Ghani","year":"2016","journal-title":"Diabetes Care."},{"key":"10.1016\/j.rce.2018.09.021_bib0600","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11010-017-3018-9","article-title":"Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: Clues to the EMPA-REG OUTCOME trial?","volume":"433","author":"Shi","year":"2017","journal-title":"Mol Cell Biochem."},{"key":"10.1016\/j.rce.2018.09.021_bib0605","first-page":"212","volume":"39","author":"Verma","year":"2016","journal-title":"Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: An important clue to the EMPA-REG OUTCOME trial?"},{"key":"10.1016\/j.rce.2018.09.021_bib0610","doi-asserted-by":"crossref","DOI":"10.1152\/physrev.00045.2011","article-title":"Mechanisms of diabetic complications","volume":"93","author":"Forbes","year":"2013","journal-title":"Physiol Rev."},{"key":"10.1016\/j.rce.2018.09.021_bib0615","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1253\/circj.67.384","article-title":"Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure","volume":"67","author":"Yamato","year":"2003","journal-title":"Circ J."},{"key":"10.1016\/j.rce.2018.09.021_bib0620","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2337\/diab.28.2.106","article-title":"Renin-angiotensin system in phlorhizin compared with alloxan diabetes in the rat","volume":"28","author":"Christlieb","year":"1979","journal-title":"Diabetes."},{"key":"10.1016\/j.rce.2018.09.021_bib0625","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/sj.ki.5000194","article-title":"Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting","volume":"69","author":"Calado","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.rce.2018.09.021_bib0630","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.medcli.2017.05.027","article-title":"Actualizaci\u00f3n del concepto del bloqueo dual del sistema renina-angiotensina-aldosterona. \u00bfUna nueva opci\u00f3n terap\u00e9utica?","volume":"150","author":"Le\u00f3n Jim\u00e9nez","year":"2018","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.rce.2018.09.021_bib0635","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.rce.2018.09.021_bib0640","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: A randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.rce.2018.09.021_bib0645","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/dom.12348","article-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"16","author":"Yale","year":"2014","journal-title":"Diabetes Obes Metab."},{"key":"10.1016\/j.rce.2018.09.021_bib0650","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.rce.2018.09.021_bib0655","doi-asserted-by":"crossref","first-page":"e0137163","DOI":"10.1371\/journal.pone.0137163","article-title":"Effect of acetazolamide on obesity-induced glomerular hyperfiltration: A randomized controlled trial","volume":"10","author":"Zingerman","year":"2015","journal-title":"PLoS One."},{"key":"10.1016\/j.rce.2018.09.021_bib0660","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ejhf.35","article-title":"The kidney in congestive heart failure: \u2018are natriuresis, sodium, and diuretics really the good, the bad and the ugly?\u2019","volume":"16","author":"Verbrugge","year":"2014","journal-title":"Eur J Heart Fail."},{"key":"10.1016\/j.rce.2018.09.021_bib0665","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1056\/NEJMra1703100","article-title":"Diuretic treatment in heart failure","volume":"377","author":"Ellison","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rce.2018.09.021_bib0670","doi-asserted-by":"crossref","first-page":"F383","DOI":"10.1152\/ajprenal.00464.2014","article-title":"Carbonic anhydrase ii binds to and increases the activity of the epithelial sodium-proton exchanger NHE3","volume":"309","author":"Krishnan","year":"2015","journal-title":"Am J Physiol Renal Physiol."},{"key":"10.1016\/j.rce.2018.09.021_bib0675","doi-asserted-by":"crossref","first-page":"R166","DOI":"10.1152\/ajpregu.00127.2011","article-title":"Increased NHE3 abundance and transport activity in renal proximal tubule of rats with heart failure","volume":"302","author":"Inoue","year":"2012","journal-title":"Am J Physiol Regul Integr Comp Physiol."},{"key":"10.1016\/j.rce.2018.09.021_bib0680","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1681\/ASN.2013060588","article-title":"Functional role of glucose metabolism osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+\/H+ exchanger isoform 3 activity in the renal proximal tubule","volume":"25","author":"Pessoa","year":"2014","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.rce.2018.09.021_bib0685","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/1479164114561992","article-title":"Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences","volume":"12","author":"Gallo","year":"2015","journal-title":"Diabetes Vasc Dis Res."},{"issue":"Suppl 1","key":"10.1016\/j.rce.2018.09.021_bib0690","first-page":"A132A1564","article-title":"SGLT2 inhibitor empagliflozin increases renal NHE3 phosphorylation in diabetic Akita mice: Possible implications for the prevention of glomerular hyperfiltration","volume":"63","author":"Fu","year":"2014","journal-title":"Diabetologia."},{"key":"10.1016\/j.rce.2018.09.021_bib0695","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2310\/6650.2002.31297","article-title":"Pathogenic mechanism, prophylaxis, and therapy of symptomatic acidosis induced by acetazolamide","volume":"50","author":"Filippi","year":"2002","journal-title":"J Investig Med."},{"key":"10.1016\/j.rce.2018.09.021_bib0700","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic diabetic ketoacidosis: A predictable detectable, and preventable safety concern with SGLT2 inhibitors","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care."},{"key":"10.1016\/j.rce.2018.09.021_bib0705","doi-asserted-by":"crossref","unstructured":"Le\u00f3n Jim\u00e9nez D, Cherney D, Bjornstad P, Castilla Guerra L, Miramontes Gonz\u00e1lez JP. Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease. Am J Physiol Renal Physiol. 2018;315:F1406\u201315.","DOI":"10.1152\/ajprenal.00384.2017"},{"key":"10.1016\/j.rce.2018.09.021_bib0710","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J."}],"container-title":["Revista Cl\u00ednica Espa\u00f1ola"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014256518302972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014256518302972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T11:46:05Z","timestamp":1556192765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014256518302972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0014256518302972"],"URL":"https:\/\/doi.org\/10.1016\/j.rce.2018.09.021","relation":{},"ISSN":["0014-2565"],"issn-type":[{"value":"0014-2565","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tratamiento diur\u00e9tico del paciente con diabetes e insuficiencia cardiaca. El papel de los inhibidores de la SGLT2 y semejanzas con los inhibidores de la anhidrasa carb\u00f3nica","name":"articletitle","label":"Article Title"},{"value":"Revista Cl\u00ednica Espa\u00f1ola","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rce.2018.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Medicina Interna (SEMI). All rights reserved.","name":"copyright","label":"Copyright"}]}}